Form 4: Bank of America Exits 10% Stake in Aptevo Therapeutics
Beneficial Ownership Update
Bank of America Corporation and its affiliates have filed a Form 4 to report they are no longer subject to Section 16 obligations for Aptevo Therapeutics Inc. after their beneficial ownership dropped below 10%.
Summary
- Bank of America Corporation, Bank of America N.A., and BofA Securities, Inc. (collectively, "Bank of America") have jointly filed a Form 4.
- The filing indicates that Bank of America is no longer subject to Section 16 of the Securities Exchange Act of 1934 with respect to Aptevo Therapeutics Inc.
- This change in reporting status is due to their beneficial ownership in Aptevo Therapeutics Inc. decreasing below the 10% threshold.
- The earliest transaction date triggering this filing was October 1, 2025.
Sentiment
Score: 5
Explanation: Neutral, as this is a procedural filing reporting a change in ownership status rather than performance or strategic news for the issuer. The impact on the issuer is indirect and requires broader context for full assessment.
Future Outlook
NA
Management Comments
- Bank of America, BANA and BOFAS are submitting this form to indicate they are no longer subject to Section 16 as their beneficial ownership has decreased below 10 percent.
Industry Context
This filing indicates a reduction in a significant institutional investor's stake in Aptevo Therapeutics, which could be interpreted by the market as a change in institutional confidence or a portfolio rebalancing. For Aptevo, it means a major shareholder is no longer a 10% owner, potentially impacting market perception and liquidity.
Stakeholder Impact
- Shareholders of Aptevo Therapeutics Inc. will note that a significant institutional investor (Bank of America and its affiliates) has reduced its stake below the 10% threshold, potentially influencing market perception and trading dynamics.
Key Dates
| Date | Description |
|---|---|
| 10/01/2025 | Earliest transaction date triggering the filing, and effective date of Joint Filing Agreements. |
| 10/03/2025 | Signature date for the Form 4 filing. |
Keywords
Aptevo Therapeutics, APVO, Bank of America, BAC, Form 4, SEC filing, beneficial ownership, institutional ownership, ownership change, Section 16
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.